# Hanke Mab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hanke-mab

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.hankebio.com
- Latest round: Series A (Aug 21, 2023)
- Investors on record: 4

## About

Established in 2013 and based in Hefei, China, Hanke Mab is a biopharmaceutical company that focuses on the development and production of new genetically engineered antibody drugs. The company is a holding company of Anke Bioengineering (Group). The company received clinical approval for the HK001 program in 2020 and the HK003 program in 2021. It has partnerships with the University of Science and Technology of China, the Cancer Hospital of the Chinese Academy of Medical Sciences, Anhui University, and Anhui Medical University. In August 2023, it raised series A+ funding from new investors.

The company's main business is the development of new genetically engineered antibody drugs. It also has three core platform technologies including AI-Computer Aided Design Platform, ISETbody Dual Antibody Construction Platform, and SCAPE Drug Screening Platform. In addition, it also provides a platform for phage antibody demonstration, bispecific antibody development, antibody durability research, and immunoassay kit development.

## Funding rounds

- Series A, Aug 21, 2023 — Guoyuan DI, Kexun Ruijin Capital, Guoyuan Innovation Investment, Shenzhen Shengzhong Investment Development

## Investors

- Guoyuan DI — Series A
- Kexun Ruijin Capital (https://capitalatlas.ai/funds/kexun-ruijin-capital) — Series A
- Guoyuan Innovation Investment — Series A
- Shenzhen Shengzhong Investment Development — Series A